Loading...
•
Dec 31, 2023
Coherus Q4 2023 Earnings Report
Coherus reported fourth quarter and full year 2023 financial results, and provided a business update.
Key Takeaways
Coherus BioSciences reported a net revenue of $91.5 million for the fourth quarter of 2023. The company is focusing on driving revenues, reducing costs, and advancing its pipeline, with constant attention to long-term shareholder value. The divestiture of CIMERLI and debt paydown improves the company's capital structure and sharpens its focus on oncology.
Net revenue was $91.5 million in the fourth quarter and $257.2 million in FY 2023.
UDENYCA® net sales were $36.2 million in the fourth quarter and $127.1 million in FY 2023.
CIMERLI® net sales were $52.4 million in the fourth quarter and $125.4 million in FY 2023.
LOQTORZI™ and UDENYCA ONBODY™ successfully launched in Q1 2024.
Forward Guidance
Coherus is introducing a guidance range of combined 2024 R&D and SG&A expenses from $250 to $265 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...